GOVERNMENT MEDICAL COLLEGE & HOSPITAL, CHANDIGARH

COMPETENCY-BASED UG CURRICULUM PHASE II BATCH 2024

Colour codes							
Pathology		Community Medicine including FAP					
Microbiology		General Medicine					
Pharmacology		General Surgery					
Clinical posting		Obstetrics and Gynaecology					
Forensic Medicine		AETCOM					
Sports and Extracurricular		Pandemic module integrated					

Abbreviations used							
LGT	Large Group Teaching	DOAP	Demonstrate, Observe, Assist, Perform				
SDL	Self- Directed Learning	DEMO	Demonstration				
SGT	Small Group Discussion	AITO	Aligned Integrated Topic				

AETCOM Modules							
Subject		Module Number					
Microbiology	Paper 1	2.1					
	Paper 2	2.8					
Pharmacology	Paper 1	2.2, 2.3					
	Paper 2	2.5					
Pathology	Paper 1	2.4					
	Paper 2	2.7					

	Topics for Integrated Learning (AITO)	Primary Department for AITO
1.	Anemia	Pathology
2.	Hypertension	Pharmacology
3.	Ischemic Heart Disease / Myocardial Infarction	Pathology
4.	Tuberculosis	Microbiology
5.	Thyroid Disease	Pharmacology
6.	Diabetes Mellitus	Pharmacology

September	November	December	January	February	March	April	May	June	July	August	September
October											
Session		December					25 th May to			Preliminary /	University
Starts 6 th		29 th to					31st May			preparatory for	Examinations
October		January 4 th					2026			university	
2025		Vacation					Vacation			examinations	

GOVERNMENT MEDICAL COLLEGE & HOSPITAL, CHANDIGARH

THEORY TIME TABLE PHASE II BATCH 2024 Teaching Hours Distribution

Subject	LGT (Hours)	SGT/Integrated/ Tutorial /Practical (Hours)	SDL (Hours)	Clinical postings (Total 540 hours in 36 weeks) Annexure 1	Total (943 Hours)
Pathology	80	170	10		260
Pharmacology	80	170	10	•	260
Microbiology	75	143	10		228
Forensic Medicine and Toxicology	12	25	08		45
Community Medicine (including FAP)	25	0	10	24	59
Clinical Subjects	60		-	540	600
Medicine					
Surgery					
Obstetrics and Gynaecology					
AETCOM		29	8		37
Sports, Yoga and Extracurricular activities		-	32		
Pandemic module integrated in subjects					
Final Total	332	537	88	564	1521

Prof. Sarabmeet Singh Lehl MEU / CC Coordinator GMCH, Chandigarh Prof. GP Thami
Director Principal
GMCH, Chandigarh

	Week 1: 6 th October to 11 th October 2025							
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM –	02:00 PM -03:00 PM				
Monday	LGTPA1.1-1.3Role of Pathologist in disease, definitions and terms in Pathology,history&evoluti on, cell cycle and role of	LGT: MI 1.1: INTRODUCTION: Historical events, scientific developments and contributions of key	SKILL LAB	Orientation /Visit to Lab Orientation /Visit to Lab				
Tuesday			Holiday					
Wednesd ay	SGT: MI 1.1: Microscope its applications, types and care.	LGT PH 1.1 Describe the principles of pharmacology, pharmacotherapeutics and define various terms in pharmacology. PH1.3. Describe nomenclature of drugs i.e., generic, branded drugs and scheduled drugs, explaining the utility of the nomenclature, cost	SKILL LAB	OSPE: MI1.6 Demonstrate the appropriate method of colLGTtion DOAP PH 1.4.Identify the common drug formulation demonstrate their use and describe their advantages	ons and drug delivery systems,			
Thursday	LGT GM: Introduction to General Medicine as a specialty	LGTPA2.1Cellinjury- causes, mechanism, types and clinical significance	SKILL LAB	OSPE: MI1.6: Demonstrate the appropriate method for the detection of microbial agents including instru DOAP PH 1.4.Identify the common drug formulation	actions to be given to patients before			
				demonstrate their use and describe their advantages and disadvantages				

Friday	LGT FM 1.1, 1.2 Introduction	LGT: MI1.2: Basic morphology, physiology	SKILL LAB	AETCOM Module 2.1 The foundation of Communication Students will form groups of 10. Session 1: 1 Hour
Saturday	LGTSU1.1 LGTSU1.2Basic concepts of homeostasis, metabolic changes in injury and their mediators Factors that affect the metabolic response to injury.	LGT PH. 1.6. Describe salient features of absorption, distribution, metabolism and excretion of drugs with emphasis on various routes of drug administration	SKILL LAB	

	Week 2: 13 th October to 18 th October 2025								
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM				
Monday	LGT PA 2.2 Cell injury- Distinguish between reversible- irreversibleinjury:mechani sms; morphology of cell injury	LGT: MI 1.2: Pathogenesis and overview of Bacterial infections	SKILL LAB	DepartmentalorientationPA1.1Roleofpathologi stindiagnosis of disease VisittoPathologylabs-Histopathology,cytology&Hematology					
				DOAP PH 1.4. Identify the common systems, demonstrate their use and d	drug formulations and drug delivery escribe their advantages and				
Tuesday	LGT PH. 1.6. Describe salient features of	s of Intracellularaccumulation		DepartmentalorientationPA1.1Roleofpathologi stindiagnosis of disease					
	absorption, distribution, metabolism and excretion of drugs with emphasis on			DOAP PH 1.4.Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and					
	LGT: MI1.3		SKILL LAB	OSPE: MI1.6 Demonstrate the appropriate method	of colLGTtion and transport of samples				

Wednesd ay	Basic principles of moLGTular biology, the	LGT PH. 1.6. Describe salient features of			DOAP PH 1.4.Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and		
Thursday	LGT GM: Introduction to General Medicine as a	LGT PA 2.5,2.6 Cellularadaptations,Patholo	lo		OSPE: MI1.6 Demonstrate the appropriate method of colLGTtion and transport of samples		
	specialty	gic calcification, gangrene			DOAP PH 1.4.Identify the common drug formulations and drug delivery systems, demonstrate their use and describe their advantages and		
Friday	LGT CM3.1 Describe the health hazards of air,	LGT: MI 1.3: Various moLGTular	SKILL LAB		AETCOM Module 2.1 [2HRS] The foundation of Communication - Focused small group session - Video, Role		
Saturday	LGTSU1.3	LGT PH. 1.6. Describe salient features of	LGT Pandemi	SGT: MI1.9:			

	Week 3: 20 th October 2025 to 25 th October 2025								
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM				
Monday			Holiday						
Tuesday	LGT PH. 1.6. Describe	LGT PA 2.7Cellular aging, Apoptosis		REVISION / Visit to Lab					
	salient features of absorption, distribution, metabolism and excretion of drugs with emphasis on			DOAP PH 1.5. Describe vario administration, their advantage demonstrate administration of,	es and disadvantages and				
Wednesday	LGT: MI 1.2, 1.4:			OSPE: MI1.6 Demonstrate the appropriate m	ethod of colLGTtion				

	Bacteriology, overview of laboratory methods used to	LGT PH. 1.6. Describe salient features of absorption, distribution, metabolism			DOAP PH 1.5. Describe vario administration, their advantage	U	
Thursday	LGT GM 29.1-26 The role of the physician in the	LGT PA 3.1 General features of acute and chronic inflammation, vascular and			OSPE: MI1.6 Demonstrate the appropriate method of colLGTtion		
	community	cellulareventsofinflammation Formative Assessment &Feedback (PA			Practical Discussion		
Friday	LGT FM 1.3 Legal Procedure and various	LGT: MI 1.2, 1.4: Virology, overview of laboratory			AETCOM Module 2.1The foundation of	SGT: MI: 1.7: Discuss the attitude &	
Saturday	LGTSU2.1 Pathophysiology of shock, types of shock &	LGT PH1.7. Describe various principles of mechanism of action of	Pandemic module 2.1 [Micro] SGT 2	Pandemic Module: 2.2			

	Week 4: 27 th October 2025 to 01 st November 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 3.2 Mediatorsof acuteinflammation	LGT: MI 1.2, 1.4: Mycology, overview of laboratory methods used to detect and causative agents of infectious diseases		DOAPPA1.1 Tissueprocessing,frozensection& stains DOAP PH 1.5. Describe various routes of drug administration, their advantages and disadvantages and		
Tuesday	LGT PH 1.7. Describe various principles of mechanism of action of drugs	LGT PA 3.3 Chronicinflammation-non-specific and granulomatous with examples		DOAPPA1.1 Tissueprocessing,frozensectio	n& stains	
	and granulomatous with examples			DOAP PH 1.5. Describe vario administration, their advantage	•	
Wednesday	SGT: MI 1.5: ColLGTtion and transportation of	LGT PH 1.7. Describe various principles of mechanism of action		OSPE: MI1.8: Demonstrate and discuss effective communication		
	samples to detect microbial agents, including instructions to be given to the patients before sample colLGTtion			DOAP: PH10.9. Calculate the dosage of drugs for an individual patient, including children, elderly, pregnant		
Thursday	LGT GM 4.1- 4.5 Causes and manifestations of fever and hyperthermia	SGTPA4.1 Repairandregeneration		OSPE: MI1.8: Demonstrate and discuss effective communication		
				DOAP: PH10.9. Calculate the individual patient, including c		
Friday	LGT CM 3.2 Describe concepts of safe and wholesome water, sanitary sources	LGT: MI 1.11: Describe the epidemiological basis		AETCOM Module 2.2 Foundation General principles: Introduction		
Saturday	LGT SU2.2 Describe the clinical features of shock and its appropriate treatment.	LGT PH 1.2. Describe evidence based medicine and rational use of drugs & discuss why these are relevant to therapeutics.	Pandemic Module 2.2 CM Emerging & Re emerging infections, early identification and control			

	Week 5: 03 rd November 2025 to 08 th November 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 5.1,5.2 Edema-Typesandpathogenesis, Hyperemia, congestion and hemorrhage	FORMATIVE ASSESSMENT MI:1.1 – 1.12 General Microbiology, Ethics & Communication		DOAPPA 2.8 Identifyanddescribeformsofcellinjuriesingrossand microscopic specimens :Fatty change liver, Gangrene bo dystrophic calcification		
				DOAP PH1.12. Define Pharma demonstrate ADR reporting	acovigilance its principles and	
Tuesday	LGT PH 1.9: SeLGTt rational drug combinations based on the PK/PD parameters with emphasis on synergism, antagonism, 'therapeutic efficacy', risk benefit ratio.	LGT PA 5.3 Pathogenesisandstagesof shock		DOAPPA 2.8 Identifyanddescribeformsofcellinjuriesingrossand microscopic specimens :Fatty change liver, Gangrer dystrophic calcification		
				DOAP PH1.12. Define Pharma demonstrate ADR reporting	acovigilance its principles and	
Wednesday			Holiday			
Thursday	LGT GM 4.7 Pathophysiology and manifestations of the sepsis syndrome	SDL PA 5.5 Embolism		DOAP: MI 1.10: Perform Gram stain to identify Practical Discussion and File of		
Friday	SDL CM3.3 Describe the aetiology and basis of water borne diseases /jaundice	LGT: MI 2.1: Role of immunological mechanisms in health		AETCOM module 2.3 Healtho	care as a right session: LGT: 2	

Saturday	LGTSU3.1 Indications and	LGT PH 1.10. Describe changes in pharmacology	LGT	
	appropriate use of blood and blood	of drugs in geriatric, pediatric and special	Pandemic	
	products and complications of blood	situations such as Pregnancy, lactation, hepatic	module 2.3	
	transfusion	and renal disorders and adjust the drug treatment	「Microl	

	Week 6: 10 th November 2025 to 15 th November 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGTPA5.4 Defineanddescribenormalhemostasis andetiopathogenesisandconsequences of thrombosis	LGT: MI 2.2: Describe the structure and functions of immune system and its components - antigens, antibodies and complement systems.		DOAPPA3.4, Identifyanddescribeacuteandchronicinflammationin gross and microscopic specimens Abscess Lu tuberculosis (lymph node, lung)		
				DOAP 10.1. Compare and co drug information and update		
Tuesday	LGT PH 1.11. Define Adverse Drug Reactions (ADRs) & their types. Identify the ADRs in the	LCT DA 5 5		DOAPPA Identifyanddescribeacuteandchronicinflamm		
	given case scenario and assess causality. LGT PA 5.5 Define and describe Ischemia/infarction its types, etiology,morphologicchanges and			DOAP 10.1. Compare and contrast different sources of drug information and update on latest information on		
Wednesday	SGT: MI 2.2 Complement system	LGTPH 1.11. Define Adverse Drug Reactions (ADRs) & their types. Identify the ADRs in the given	the ADRs in the given Perform ZN stain to identify the di		the different causative	
		case scenario and assess causality.		DOAP: PH 10.8. Describe Es dose combination, Over the c		
Thursday	LGT GM 4.8 Heat cramps, heat exhaustion and heat stroke	SDL PA 5.5 Embolism		DOAP: MI 1.10: Perform ZN stain to identify	the different causative	
				DOAP: PH 10.8. Describe Es dose combination, Over the c	· · · · · · · · · · · · · · · · · · ·	
Friday	LEC FM 1.4 FM 1.6, 1.7, 1.8 Courts in India Offenses in Court & Dving	SGT: MI 2.2 Antigen -Antibody reaction		AETCOM Module 2.4: Work Students will go in Groups of	-	
Saturday	LGTSU4.1 History in a case of Burns with documentation and physical	LGT PH. 10.12. Describe overview of drug development including phases of clinical trials	LGT Pandemic			

	Week 7: 17 th November 2025 to 22 nd November 2025					
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 6.1 Define and classify neoplasia. Describe the characteristics of neoplasia, differentiate between benign and malignant neoplasms	LGT: MI 2.3 Host immune responses in Microbial infections (humoral and cellular immune response).		DOAPPA 5.6 CVC(Lung,Spleen, liver) Infarct Kidnev Tutorial: Pharmacokine	tic Exercises	
Tuesday	LGT PH2.1 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of adrenergic and antiadrenergic drugs	LGT PA 6.2 MoLGTularbasis ofcancer,Role of genetic and epigenetic alterations with emphasis common cancers like breast and colon cancers		DOAPPA 5.6 CVC(Lung,Spleen, liver) Infarct Kidney Tutorial: Pharmacokine	tic Exercises	
Wednesday	LGT: MI 2.5: Discuss the principles and applications of laboratory tests used in diagnostic microbiology based on the host's immune response.	LGT PH2.1 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of adrenergic and antiadrenergic drugs		DOAP: MI 1.10: Perform routine stool ex Tutorial: Pharmacodyna	•	
Thursday	LGT GM 4.9, 4.14 Fever of unknown origin	LGT PA 6.2 MoLGTularbasis ofcancer,Role of genetic and epigenetic alterations with emphasis common cancers like breast and colon cancers		DOAP: MI 1.10: Perform routine stool ex Tutorial: Pharmacodyna		
Friday	LGT CM3.4 Describe the concept of solid waste, human excreta and sewage disposal	SGT: MI 2.4 Discuss the immune response in different types of		AETCOM Module 2.4: care team Students will		
Saturday	LGTSU4.2 LGTSU4.3 Clinical features, diagnose type and extent of burns and plan	LGT PH2.1 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug	SGT FM 1.5 Moot Court			

	Week 8: 24 th November 2025 to 29 th November 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 6.3 Carcinogenesis-viral,physical,	LGT: MI 2.6: Discuss the immunological basis of disease		DOAPPA 6.7 Lipoma,Squamouscell carci	noma, Metastasis	
	chemical prevention through active and passive immune prophylaxis. Discuss the importance of herd			DOAP. PH 2.3. Explain the rationale and demonstrate the emergency use of various		
Tuesday	AITO Hypertension. LGT., AN5.4, 5.7, PY5.7. PH2.1 (Sharing).	SGTPA6.4 Effectsoftumorincludingparaneoplastic syndromes		DOAPPA 6.7 Lipoma,Squamouscell carcinoma, Metastasis		
	Describe types, salient pharmacokinetics, pharmacodynamics. therapeutic			DOAP. PH 2.3. Explain the rationale and demonstrate the emergency use of various		
Wednesday	SGT: MI2.7: Immunological mechanisms in hypersensitivity, and discuss	LGT PH2.2: Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and	Case based discussion: Differentiate agents of	DOAP: MI 1.10: Perform Gram stain to ident	ify the different	
	the laboratory methods used in their detection.	demonstrate OPC poisoning management	malignant malaria from agents of benign malaria reported in peripheral	Certifiable Competency: PH a correct, rational and legible	•	
Thursday	LGT GM 4.13-4:15, 4.18 Specific lab testing and	LGT 6.5 Laboratory diagnosis of cancer including moLGTular profiles of tumours, tumor		DOAP: MI 1.10: Perform Gram stain to ident	ify the different	
	imaging in fever markers and future of cancer diagnostics			Certifiable Competency: PH a correct, rational and legible	•	
Friday	LEC FM 8.1 8.2	SGT: MI2.7: Immunological mechanisms in autoimmune		AETCOM Module 2.4: Worteam The Groups will then i		

Saturday	LGTSU5.1 LGTSU5.2	LGT PH2.2: Describe types, salient	PANDEMIC MODULE 2.4	
		pharmacokinetics, pharmacodynamics, therapeutic	CM	
	Normal wound healing and	uses, adverse drug reactions of cholinergic and	VISIT TO PHC	
	factors affecting healing.	anticholinergic drugs and demonstrate OPC		
		poisoning management		

	Week 9: 1st December 2025 to 6th December 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 6.6 Immunologyandimmuneresponse to cancer	SGT: MI2.7: Immunological mechanisms in immunodeficiency states and discuss the laboratory methods used in their detection		SGTPA7.1 Describe the diagnostic role of cyto exfoliativecytologyincludingtechnic and Pap smear		
				Certifiable Competencies Assessn forms and DDS)	nent: PH.1.4 and PH. 1.5 (Dosage	
Tuesday	LGT PH2.2: Describe types, salient pharmacokinetics, pharmacodynamics,	LGTPA8.1,8.2,8.3 Principlesandmechanismsinvolved in		SGTPA7.1 Describe the diagnostic role of cyto	logy, basis of	
	therapeutic uses, adverse drug reactions of cholinergic and anticholinergic drugs and demonstrate OPC poisoning	immunity, Mechanism of hypersensitivity reactions HLA system, Transplant rejection		Certifiable Competencies Assessment: PH.1.4 and PH. 1.5 (Dosage forms and DDS)		
Wednesday	SDL: MI 2.8 Describe the immunological	LGTPH2.4. Explain salient pharmacokinetics, pharmacodynamics,		DOAP: MI 1.10: Perform ZN stain to identify the diff	ferent causative agents of	
	mechanisms involved in transplantation, tumour immunity and their applications in disease	therapeutic uses, adverse drug reactions of skeletal muscle relaxants		PH10.10. Identify when therapeutic a particular patient, determine timin		
Thursday	LGT GM 6.1-6.3 HIV: Clinical features	SGTPA8.6HIV/AIDS		DOAP: MI 1.10: Perform ZN stain to identify the diff	ferent causative agents of	
				PH10.10. Identify when therapeutic a particular patient, determine timin	č č	
Friday	SDL CM3.3 Describe the aetiology and basis of water borne diseases	LGT: MI 3.1: Etiopathogenesis, clinical features,		AETCOM Module 2.5 Bioethics Ca and Decision Making Session 1: Gr	-	
Saturday	LGTSU5.3 Types and management of wounds.	LGTPH2.5. Explain types, salient pharmacokinetics, pharmacodynamics,	Formative Assessment			

	Week 10: 8 th December 2025 to 13 th December 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGTPA8.4, 8.5 Define autoimmunity ,enumerate autoimmune disorders and pathogenesis . Pathogenesis of systemic Lupus Erythematosus	. FORMATIVE ASSESSMENT MI:2.1 – 2.8 Basic Immunology & Immunological disorders		SGTPA10.1-10.4 Pathologyof Malaria, Cyst Pathogenesis of commonbacterial, viral, pro helminthic diseases		
				Tutorial: Adrenergic and Adrugs	Anti-adrenergic	
Tuesday	SDL PH10.5. Identify and apply the legal and ethical regulation of prescribing drugs especially when	SGT PA 10.5 Define and describe the pathogenesis and pathology and laboratory findings in COVID		SGTPA10.1-10.4 Pathologyof Malaria, Cyst	ticercosis , Leprosy	
	prescribing drugs especially when prescribing for controlled drugs, off-label medicines, and prescribing FORMATIVE ASSESMENT AND			Tutorial: Adrenergic and Adrugs	Anti-adrenergic	
Wednesday	SGT: MI 3.1: Rheumatic fever case-based	LGT PH2.6: Explain types, salient pharmacokinetics, pharmacodynamics,		DOAP: MI 1.10: Perform routine stool exar	mination to identify	
	discussion	therapeutic uses, adverse drug reactions of anti-histaminics and explain		Tutorial: Cholinergic and drugs	Anti-cholinergic	
Thursday	LGT GM 6.3-6.6, 6.10 HIV: Opportunistic infections and	LGT PA9.1 Describe the pathogenesis and Pathology of Amyloidosis	DOAP: MI 1.10: Perform routine stool ex		mination to identify	
	diagnostic tests			Tutorial: Cholinergic and drugs	Anti-cholinergic	
Friday	LGT CM3.5 Describe the standards of housing and the effect of housing	.LGT: MI3.2: Describe the classification etio-		AETCOM Module 2.5 Case Introduction	TUTORIAL- COVID	

Saturday	LGTSU5.4 Medico legal aspects of wounds.	LGT PH2.7 Define pain and enumerate drugs used for pain. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of analgesics including NSAIDs (except opioids)	CASE STUDIES- HEMODYNAMICDISORDERS , NEOPLASIA	
----------	--	--	--	--

	Week 11: 15 th December 2025 to 20 th December 2025					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 11.1-11.3 Cytogenetic abnormalities, tumor and tumor like conditions in infancy and childhood, storage disorders	SGT: MI 3.2 Infective endocarditis (IE). case-based discussion		DOAP PA9.2 Amyloidosis kidney, Spleer DOAP 10.1. Compare and contrast differ information and update on latest information	ent sources of drug	
Tuesday	SDL PH10.5. Identify and apply the legal and ethical regulation of prescribing drugs especially when prescribing for controlled drugs, off-label medicines and	AITO Hypertension PA 12.3, GM 8.1. Correlation LGTPA12.1-12.2., Environmental and nutritional diseases Pathogenesis of obesity and its consequences ,metabolic syndrome,Disorders caused by air pollution, tobacco, alcohol, Protein calorie malnutrition		DOAP PA9.2 Amyloidosis kidney, Spleer DOAP 10.1. Compare and contrast differ information and update on latest information	ent sources of drug	
Wednesday	LGT: MI 3.3			DOAP: MI 1.10: Perform Gram stain to identify the difference	ent causative agents of	

	Discuss the diagnostic modalities of IE available	LGT PH2.8. Devise management plan for a case of gout, arthritis and migraine using		SGT: SKILL LAB. PH1.8. Demonstrate the mechanism of action & effects of common prototype drugs on human body
Thursday	LGT GM 6.14-6.16 HIV: Antiretroviral therapy	LGT PA 33.1,33.2 Describe the risk factors pathogenesis,		DOAP: MI 1.10: Perform Gram stain to identify the different causative agents of
		pathology and naturalhistoryofsquamouscellcarcinoma and basal cell carcinoma oftheskin		SGT: SKILL LAB. PH1.8. Demonstrate the mechanism of action & effects of common prototype drugs on human body using computer assisted learning
Friday	LEC FM 8.3	SGT: MI 3.4: Diagnose a clinically suspected case of		AETCOM Module 2.5 Autonomy and Decision Making Session 3 & 4
Saturday	LGTSU6.1 Aetiology and pathogenesis of	LGT PH2.8. Devise management plan for a case of gout, arthritis and migraine	SGD/ BED SIDE	

	Week 12: 22 nd December 2025 to 27 th December 2025						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	InternalAssessmentI(Theory)SGT:MI3.5:Discuss the etio-pathogenesis and diagnostic modalities available to rule outinfective causes of PUO			InternalAssessmentI(Practical)			
				Certifiable Competency Assessment: Information Sources)	PH.10.1 (Drug		

Tuesday	SDL. PH10.7. Describe Pharmacogenomics and Pharmacoeconomics and manage genomic & economic issues in drug use and find out the price of given medication(s).	SGTPA33.3 Describethedistinguishingfeatures between a nevus and melanoma. Describetheetiology,pathogenesis,risk factorsmorphologyclinicalfeaturesand metastases of melanoma skin		Internal Assessment I (Practical) Certifiable Competency Assessment: PH.10.1 (Drug Information Sources)
Wednesday	LGT: MI 3.6 Classification & detail of the enteric fever pathogens. The evolution of the clinical course and	LGT PH3.1. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of General anaesthetics, and pre-anaesthetic medications		DOAP: MI 1.10: Perform ZN stain to identify the different causative agents of File Checking
Thursday			Holiday	
Friday	LGT CM3.6 Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease	SGT: MI 3.6: Enteric fever:		SGT PA33 -SKIN TUMORS
Saturday	LGTSU6.2 Prophylactic and therapeutic antibiotics. Planning of appropriate management	LGT PH3.1. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of General anaesthetics, and pre-anaesthetic medications	LGT CM3.7, 3.8, Formative Assessment	

	Week 13 : 29 th December 2025 to 4 th January 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
	WINTER VACATION						

	Week 14: 5 th January 2026to 10 th January 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	AIToAnemiaSession1:SGT1hrRecapitulationof AITO Anemia phase 1 and PA 13.1 BI6.11, PY2.3NestingPA13.1Describehematopoiesisand extramedullary hematopoiesis PA 13.1 Describethe role of anticoagulants in hematologyFormativeassessmentandFeedback (PA9,11, 33)	.LGT: MI 3.9 Enumerate the common infective causes of anemia and describe the mechanisms involved in causing anemia by them		DOAP PA 33.4 Identify, distinguish and describe commontumorsofskin-Nevus,Melanoma,SCC DOAP. PH10.11. Identify and apply drug Regulations principles, acts and legal aspects related of drug discove and clinical use			
Tuesday	SDL. PH10.7. Describe Pharmacogenomics and Pharmacoeconomics and manage genomic & economic issues in drug use and find out the price of given medication(s).	AITO Session2: LGT:1hrs PA13.2 IM9.1LinkerCasetobediscussed. Nesting Define and classify anemia Enumerateanddescribetheinvestigationof anemia		DOAP PA 33.4 Identify, distinguish and describe commontumorsofskin-Nevus,Melanoma,SCC DOAP. PH10.11. Identify and apply drug Regulations principles, acts and legal aspects related of drug discover and clinical use			
Wednesday	SGT:MI 3.10: Describe the morphology, life cycle, pathogenesis, laboratory diagnosis, prevention and control of the common parasites causing anaemia	LGT. PH3.2. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of different sedative and hypnotic agents and explain pharmacological basis of seLGTtion and use of different sedative and hypnotic		DOAP: MI 1.10: Perform routine stool examination to Certifiable Competency Assessmen Reporting)	•		
Thursday	OG2.1 LGT Describe & discuss the development and anatomy of female reproductive tract. relationship to other pelvic organ and	AIToAnemiaSession4: SDL 1hr PA 14.1 Describe iron metabolism, Describe the etiology, investigations and differential diagnosisofmicrocytic		DOAP: MI 1.10: Perform ZN stain to identify the different Certifiable Competency Assessment Reporting)	-		
Friday	LGT CM5.1 Describe the common sources of various nutrients and special nutritional	SDL: MI 3.11 Laboratory diagnosis and prevention of		AETCOM Module 2.5 Autonomy an Session 5:Case resolution 2 hour	d Decision Making		
Saturday	LGTSU7.1 Planning and conduct of Surgical audit.	LGT. PH3.3. Describe types, salient pharmacokinetics. pharmacodynamics.	FAMILY ADOPTION				

	Week 15: 12 th January 2026 to 17 th January 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM		
Monday	AITOAnemiaSession 6:LGT:1hrs PA15.1,PA15.2 IM9.2 Nesting PA15.1Describe the metabolism of Vitamin B12 and the etiology and pathogenesis of B12 deficiency,laboratory investigations of macrocytic anemia Enumeratethedifferencesanddescribe	SDL: MI:3.13: Describe the epidemiology, the etio-pathogenesis, evolution complications, opportunistic infections, diagnosis, prevention and the principles of management of HIV		DOAP 13.3,13.4 Describe colLGTtion of samples, identify anti coagulants, instruments, RBC Count, Certifiable Competency Assessment:: PH10.9. Calculate the dosage of		
Tuesday	LGT. PH3.3. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in epilepsy and devise management plan for a case of uncontrolled seizure	FeedbackInternalAss.I AITOAnemiaSession9:LGT:1hr PA 16.1-16.3 PE 29.4 Nesting Define and classify hemolytic anemias ,pathogenesis,clinical features, hematologicindicesandperipheral blood picture of sickle cell anemia and thalassemia ,acquired hemolytic anemias		DOAP 13.3 ,13.4 Describe colLGTtion of samples, Certifiable Competency Assessment: : PH10.9. Calculate the dosage of drugs for an individual		
Wednesda y	. SGT: MI 4.1: Define and differentiate between diarrhea, dysentery and food poisoning. Enumerate the microbial	LGT. PH3.4 Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs of opioid analgesics and explain the special instructions for use of opioids.		Interpretational exercises: MI 3.7: DOAP. PH3.9. Describe		
Thursday	OG3.1 LGT/Seminar Describe physiology of ovulation, fertilization, implantation and gametogenesis VI Integration with	AIToAnemiaSession4: SDL 1hr PA 14.1 Describe iron metabolism, Describe the etiology, investigations and differential diagnosisofmicrocytichypochromic anemia PE13.1PE13.4Nesting		DOAP: MI 1.10: Perform routine stool DOAP. PH3.9. Describe the drugs that are abused and cause addiction (dependence, addiction, stimulants, depressants.		
Friday	LEC FM 8.5 Preservation of	LGT: MI 4.2 Describe the epidemiology, morphology, pathogenesis, clinical features and		AETCOM LGT: MI 4.2 Describe the		

Saturday	LGTSU7.2 Principles and steps	LGT. PH3.5 (Depress	ion)			SGT	FM 8.8,	
	of clinical research in General	Describe types,	salient	pharmacokinetics,	pharmacodynamics,	8.9	Basic	

	Week 16: 19 th January 2026 to 24 th January 2026							
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM			
Monday	SUMMATIVE ASSESSMENT -I			DOAP PA 13.4 Perf and DLC (Certifiab				
				Certifiable Competer Describe parts of a co	•			
	LGT. PH3.5 (Depression)	AITOAnemiaSession10:LGT:1hrs PA17.1IM9.11 Nesting		DOAP PA 13.4 Perf and DLC (Certifiab				
		PA17.1Enumeratetheetiology, pathogenesis and findings in		Certifiable Competer Describe parts of a co				
Tuesday	HOLIDAY ON Tuesday probably							
Wednesday	PATHOLOGY	LGT. PH3.5(Psychosis)		PRACTICAL ASSE	SSMENT - I			
				Certifiable Competer Describe parts of a co				
Thursday	OG4.1LGT/seminar(b)	SGT PA 18.1 Causesofleucocytosis,leucopenia, lymphocytosis and leukemoid reactions		PRACTICAL ASSE	SSMENT - I			
	Describe and discuss anatomy and functions of placenta.	FORMATIVE ASSESMENT AND FEED BACK PA 13-17		Certifiable Competer Describe parts of a co				
Friday	LGT CM5.2 Describe and demonstrate the correct method of performing a nutritional	LGT: MI 4.2 Describe the epidemiology, morphology, pathogenesis,		AETCOM Module 2 Decision Making Ca				

Saturday LGTSU8.1 Ethics as it General Surgery.	LGT. PH3.5(Psychosis)	FAMILY ADOPTION	
---	-----------------------	--------------------	--

	Week 17: 26 th January 2026 to 31 st January 2026						
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday		HOLIDAY					
Tuesday	LGT. PH3.6. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug	LGTPA 18.2 Etiopathogenesis, classification and hematologic features of acute and	REVISION / LOG BOOK CH		OOK CHECKING		
	reactions of drugs used in anxiety disorders. Discuss about general goals of Pharmacotherapy for the management of above disorders	chronicleukemia		DOAP. PH10.2 Performance evaluation of the dru			
Wednesday	LGT: MI 4.3: Describe the epidemiology, morphology,	LGT. PH3.7. Explain types, salient pharmacokinetics, pharmacodynamics,		Interpretational exercises: MI 3.8: Read and interpret the results of various			
	pathogenesis, clinical features and diagnostic modalities of bacterial, and fungal agents causing dysentery	therapeutic uses, adverse drug reactions of drugs used for Parkinsonism and other neurodegenerative disorders. Write a		DOAP. PH10.2 Perform a critical evaluation of the drug promotional			
Thursday	OG4.1LGT(a) Describe & discuss fetal circulation at	LGTPA 18.2 Etiopathogenesis, classification and		Interpretational exerc Appropriate laborato			
	birth and factors influencing fetal growth and development. hematologic features of acute and chronicleukemia			Discussion, File and Checking	Log-Book		
	VI Integration with Anatomy						
Friday	LEC FM 8.8 Describe basic methodologies in treatment of poisoning:	SGT: MI 4.3 Describe the epidemiology, morphology,		CASE STUDIES – I 17ANEMIAS	PA 14-		
Saturday	LGTSU8.2 Demonstrate Professionalism and empathy to the patient undergoing	LGT. PH3.8. Identify and manage methanol poisoning and chronic ethanol intoxication	SDL FM 8.10 Describe the general principles				

	Week 18: 02 nd February 2026 to 07 th February 2026				
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM
Monday	LGTPA 19.1,19.2 CausesanddifferentiatingfeaturesofL AP Pathogenesis and pathology of tubercular lymphadenitis	LGT: MI: 4.5: Enumerate the bacterial, viral, parasitic and fungal agents of food poisoning and discuss their pathogenesis, clinical course and laboratory diagnosis		DOAP PA 14.2 and 15.3 and 1 Microcytic , Macrocytic and he Sickle cell) Anemias	emolytic (Thalessemia and
				DOAP: PH10.13. Demonstrate interaction with pharmaceutica get/disseminate authentic information.	l representative/media to
Tuesday	SUMMATIVE ASSESSMENT SGTPA19.4			DOAP PA 14.2 and 15.3 and 1	6.2
		Causesandpathologyof splenomegaly		DOAP: PH10.13. Demonstrate interaction with pharmaceutica get/disseminate authentic information of the pharmaceutical get/disseminate authentic information of the pharmaceutic information of the	l representative/media to
Wednesday	SGT: MI: 4.5: Enumerate the parasitic and fungal	LGT. PH4.1Explain types, salient pharmacokinetics, pharmacodynamics,		Case based discussion MI 3.12 Clinical exercise with periphera	
	agents of food poisoning and discuss their pathogenesis, clinical course and laboratory	therapeutic uses, adverse drug reactions of drugs used for different anaemias and thrombocytopenia.		Certifiable Competency Assecritical evaluation of the drug p	
Thursday	OG8.1 LGT	LGT PA 19.3 Pathogenesis, pathology and differentiating		Interpretational exercises: MI 3 results of various laboratory in	_
	Describe and discuss objective of antenatal care assessment of period of	featuresofHodgkinandNon- Hodgkin lymphoma FormativeassessmentandFeedback		Certifiable Competency Assecritical evaluation of the drug p	
Friday	SDL CM5.3 Define and describe common nutrition related health	LGT: MI: 4.5: Enumerate the bacterial and viral,		AETCOM Module 2.6 Autono	•

Saturday	LGTSU8.3 Discuss Medico- legal issues in surgical practice		FAMILY ADOPTION PROGRAMME VISIT 3	
----------	---	--	--------------------------------------	--

	Week 19: 09 th February 2026 to 14 th February 2026						
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	l LGTPA 20.3 Featureofplasmacell myeloma	SDL: MI 4.6 Describe the infective etiology, pathogenesis and clinical course of Acid peptic disease (APD) and discuss the laboratory diagnosis and		DOAP PA 14.2 and 15.3 and 1 Microcytic , Macrocytic and he Sickle cell) Anemias (Certification of the cell) Anemias (Certification of the cell)	emolytic (Thalessemia and		
	management of the causative agent of APD.			AITO-Hypertension. SGT. PH10.15, GM8.15 (Nesting). Describe methods to improve adherence to treatment and			
Tuesday	LGT. PH4.3Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug	LGTPA 20.1-20.2 Normal hemostasis and		DOAP PA 14.2 and 15.3 and 1	6.2		
	reactions of Fibrinolytics and Antifibrinolytic agents.	hemorrhagicdisorders(ITP, hemophilia) Laboratoryfindingsanddiagnosisof DIC and Vit K deficiency Formativeassessmentand feedback PA		AITO-Hypertension. SGT. PH Describe methods to improve a motivate patients with chronic prescribed	adherence to treatment and		
Wednesday	LGT: MI 4.7, 4.8 Describe the epidemiology, etiopathogenesis,	LGT. PH4.4. Explain types, salient pharmacokinetics, pharmacodynamics,		DOAP: M1 4.4 Stool microscopic examination	and discuss common		
	clinical features and complications of viral hepatitis	therapeutic uses, adverse drug reactions of Antiplatelets agents.		SUMMATIVE PRACTICAL	ASSESSMENT 1		
Thursday	OG6.1LGT/Seminar	SGTPA21.1-21.2 Blood group systems,		Case based discussion MI:3.12 peripheral blood smear examin			

	Describe and discuss the clinical	indicationandprinciplesofcompatibilit ytesting, blood components and their		SUMMATIVE PRACTICAL ASSESSMENT 1	
Friday	SDL FM 8.10 Describe the general principles of Analytical Toxicology	SGT: MI 4.7. 4.8 Describe the epidemiology,		AETCOM Module 2.7 INTRODUCTION	Pandemic Module Session 4 Pharma 1 Hr
Saturday	LGTSU9.1 Biochemical, microbiological, pathological and imaging investigations s in a surgical patient.	LGT. PH4.5. Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Diuretics, antidiuretics-vasopressin and analogues	LGT FM 9.1 Treatment of Poisoning by Phosphorus, Barium, Iodine Sulphuric, nitric and HCL		

	Week 20: 16 th February 2026 to 21 st February 2026							
Day	08:00-09: CM8.2 Describe and discuss the epidemiological and control measures including	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM – 04:00 PM			
Monday	LGTPA 21.4,21.5 Transfusionreactions, steps in investigation of a transfusion reaction principles and procedure of autologous transfusion	LGT: MI 4.7, 4.8 Discuss the modalities in laboratory diagnosis, with special emphasis on viral markers and preventive strategies for viral hepatitis caused by hepatitis		AITOAnemiaSessio hrsASSESSMENT Certifiable Compet Assessment: PH10.	tency			

Tuesday	AITO-Hypertension. LGTPH4.5. PY 5.8. PY 5.9 Correlation. Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of Diuretics, antidiuretics- vasopressin and analogues	SGTPA21.5 Infectionstransmittedbyblood transfusion		AITOAnemiaSession 13:2 hrsASSESSMENT Certifiable Competency Assessment: PH10.15,. Describe
Wednesday	SDL: MI 4.9 Laboratory test, history and clinical presentation in a suspected case of viral hepatitis, interpret the type and progress of viral hepatitis based on the laboratory report of viral markers in a case of	AITO-Hypertension. LGT. PH4.6., PY 7.2. Nesting. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs modulating renin angiotensin aldosterone system.		DOAP: M1 4.4 Stool microscopic examination and Certifiable Competency Assessment: DOAP: PH10.13.
Thursday	OG.7.1(b)LGT Describe and discuss physiological changes in pregnancy.	LGTPA 23.1,23.2 Etiopathogenesis and clinical and pathologicfeaturesoforalcancer, carcinoma esophagus FormativeassessmentandFeedback (PA 21)		DOAP: M1 4.4 Stool microscopic examination and Certifiable Competency Assessment: DOAP: PH10.13.
Friday	SDL CM5.3 Define and describe common nutrition related health disorders (including	. LGT: MI 5.1 Microbial agents causing anaerobic infections their		AETCOM Module 2.7 Autonomy and Decision Session 2&3: SDL: 2
Saturday	LGTSU9.2 Biological basis for early detection of cancer and multidisciplinary approach in management of cancer SU9.3 Communicate of results of surgical investigations.	AITO Hypertension. PH4.7., SGD: GM8.13 (Nesting). Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of hypertension	FAMILY ADOPTION PROGRAMME VISIT 4	

	Week 21: 23 rd February 2026 to 28 th February 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	

Monday	LGTPA 23.3 ,23.4 Etiopathogenesis and clinical and pathologicfeaturesofpepticulcer disease. Etiopathogenesisofcarcinoma	FORMATIVE ASSESSMENT MI 4.1-4.9 Gastrointestinal and Hepatobiliary system		DOAPPA18.2AML, CML, CLL DOAP: PH10.6. Perform a critical appraisal of a given prescription and suggest ways to improve it	
Tuesday	AITO Hypertension. LGTPH4.7., GM8.13 OG!2.1 (Nesting). PH4.7Devise plan for pharmacologic management of	SGTPA23.6,23.7 Etiopathogenesisandpathologicfeatures of IBD and malabsorption		DOAPPA18.2AML, CML, CLL	
	hypertension with Diabetes, Pregnancy induced hypertension and hypertensive	syndrome		DOAP:PH10.6. Perform a critical appraisal of a given prescription and suggest ways to improve it	
Wednesday	Lab diagnosis and management for	SGD AITO-Hypertension assessment SGD AITO-Hypertension-RefLGTtions		DOAP: M1 4.4 Stool microscopic examination and discuss common	
	agents causing anaerobic infections	and feedback		DOAPPA19.6Grossspecimenof enlarged spleen, HL, NHL	
Thursday	OG7.1(a)LGT	Litopatilogenesisandpatilologie		DOAP: M1 4.4 Stool microscopic examination and discuss common	
	Describe and discuss physiological changes in pregnancy (Genital tract CVS)	features of Carcinoma colon		DOAPPA19.6Grossspecimenof enlarged spleen, HL, NHL	
Friday	SDL Anaesthetics and muscle relaxants	LGT: MI 5.2, 5.3 Explain the etiopathogenesis,		AETCOM Module 2.7 Autonom and Decision SGT: MI 5.2, 5.3 Explain the	

Saturday	Assessment I	.LGT. PH4.8Describe types,	SDL Anaesthetics ar relaxants	nd muscle	
	GENERAL SURGERY	salient PK/pd, therapeutic uses, adverse drug	Session 2 Feedback		
		reactions of drugs used for			
		the management of			
		ischemic heart disease			
		(stable, unstable angina			
		and myocardial infarction),			
		peripheral vascular disease			
		and devise management			
		plan for a patient of acute			
		myocardial Infarction			

	Week 22: 02 nd March 2026 to 7 th March 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGTPA24.1 Describebilirubin metabolism, etiopathogenesis of Jaundice, distinguish direct and indirect	. SGT: MI 5.2, 5.3 Explain the etiopathogenesis, clinical course & laboratory diagnosis of bone & joint infections caused by viral agents		DOAP PA21.6 PERFOR GROUPING PERFORM CROSS MA		
	hyperbilirubinemia			DOAP: PH10.14. Comm patient regarding optimal		
Tuesday	LGT. PH4.8IHD	SGT PA 24. 2,24.3 Describetheetiologyandpathogenesis,		DOAP PA21.6 PERFOR GROUPING	M BLOOD	
		complications of viral and toxic hepatitis and hepatic failure		DOAP: PH10.14. Comm patient regarding optimal using empathy and profes contracentives anti TR	use of a drug therapy	
Wednesday			Holiday	HOLI		
Thursday	OG8.7 LGT	SDL PA 24.4 Pathology of Alcoholic liver disease and Cirrhosis		DOAP: M1 4.4 Stool microscopic examination and discuss		
	Enumerate indications and type of vaccination in			LOG BOOK AND PRACTICAL BOOK CHECKING		
Friday	SDL CM5.4 Plan and recommend a suitable diet for	.LGT: MI 5.3 5.4 Etiopathogenesis and clinical course of skin and		AETCOM Module 2.7 Autonomy and	LGT: MI 5.3 5.4 Laboratory diagnosis	

	LGT GM26.23 Common Viral Respiratory Infections, COVID-19, SARS, Influenza	LGT: PH.4.9. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of heart failure. Devise management plan for heart failure patients anddescribe the strategies to prevent long term complications of heart failure	FAMILY ADOPTION PROGRAMME VISIT 5	
--	--	---	--	--

	Week 23: 09 th March 2026 to 14 th March 2026								
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM				
Monday	LGTPA 24.5 Metabolic Liver disease (NAFLD), Etiopathogenesisandcomplicationsof portal hypertension	LGT: MI 5.1, 5.3 Gas gangrene, etiology, pathology and diagnosis.		DOAP PA21.6 PERFORM BLOOGROUPING PERFORM CROSS MATCHING (Certifiable Competency)					
				DOAP: PH10.16. Demonstrate an understanding of the caution in					
Tuesday	LGT: PH.4.9. CHF	SGT PA 24.6 LIVER FUNCTION TESTS AND		DOAP PA21.6 PERFORM BLOOD GROUPING					
		VIRAL HEPATITIS SEROLOGY PANEL		DOAP: PH10.16. Demonstrate an understanding of the caution in					
Wednesday	SDL: MI 5.5 Describe the etiopathogenesis, clinical course,	LGT. PH4.10. Explain salient PK/PD, therapeutic uses, adverse drug reactions		DOAP MI 7.4 Gram Stain/ Albert-s	tained smear of				
	complications and laboratory diagnosis of mycobacterial infections involving skin & soft tissue with special emphasis on sample colLGTtion from/of of drugs used for cardiac arrhythmias. Devise a plan to manage a patient with supraventricular, ventricular arrhythmias.			DOAP 23.9 Peptic ul ulcer, carcinoma colo					

Thursday	OG9.1LGT Describe and discuss aetiology and types of abortions.	SDL PA 24.4 Alcoholicliver disease and cirrhosis		DOAP MI 7.4 Gram Stain/ Albert-stained smear of throat swab and of throat swab and correlate with the clinical findings DOAP 23.9 Peptic ulcer, intestinal ulcer, carcinoma colon
Friday	LEC FM 9.1 Treatment of Poisoning by	LGT: MI 5.4 Differentiate between infective and		AETCOM Module 2.8 What does it mean to be a family member Session 1:
Saturday	LGT GM26.29-30 Malaria	LGT. PH4.10. Cardiac arrhythmias	SGT/ AUTOPSY/ DOAP FM 9.5 Organophosphates,	

	Week 24: 16 th March 2026 to 21 st March 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM –	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGT PA 24.7 Etiopathogenesis Morphology of Hepatocellular carcinoma	FORMATIVE ASSESSMENT MI 5.1- 5.5 Musculoskeletal system, Skin and Soft tissue infections		DOAP:2hrs24.6 LIVER FUNCTION TESTS AND VIRAL HEPATITIS SEROLOGY PANEL(Certifiable Competency)		
				DOAP: PH10.17. Demonstrate ability to educ public & patients about various aspects of dru		
Tuesday	LGT. PH4.11. Explain salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used for the management of dyslipidaemias and enumerate drugs leading	SGT PA 24.8 Pathology of ChoLGTystitis and Cholelithiasis FORMATIVE ASSESMENT AND FEED BACK PA 23		DOAP:2hrs 24.6 LIVER FUNCTION TESTS AND VIRAL HEPATITIS SEROLOGY PANEL(Certifiable Competency)		
	to dyslipidaemias				nonstrate ability to educate at various aspects of drug use	
Wednesday	LGT: MI 6.1, 6.2			DOAP MI 7.4 Gram Stain/ Albert-sta	ained smear of throat swab	

	Microbial agents causing meningitis, their pathogenesis and clinical course.	LGT. PH5.1. Devise management of various stages of Bronchial asthma, COPD. Explain salient PK/PD, therapeutic		DOAPPA 24.9 Alcoholichepatitis, Ci	rrhosisof liver, Hepatocellular
Thursday	OG9.2LGT	LGTPA 25.1,25.2 Etiopathogenesis,morphologyand complications of		DOAP MI 7.4 Gram Stain/ Albert-stained smear of throat swab	
	Describe and discuss MTP Act and steps and methods of MTP. pneumonia and lung abscess		DOAPPA 25.4 Alcoholichepatitis, Cirrhosisof liver, HCC		
Friday	SDL CM5.4 Plan and recommend a suitable diet for the individuals and	SGT: MI 6.1.6.2 Case discussion, laboratory diagnosis and management		AETCOM Module 2.8 What does it	SDL: MI 6.2 Discuss the microbial
Saturday			Holiday Id-ul_Fitr		

	Week 25: 23 th March 2026 to 28 th March 2026							
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM			
Monday	LGTPA 25.1,25.2 Etiopathogenesis,morphologyand complications of pneumonia and lung abscess	SGT: MI: 6.3 Identify the microbial agents causing meningitis from the given history and clinical findings. Interpret the findings and culture report of SF to diagnose the case		DOAP PA 25.7 Grossandmicroscopicfeaturesoflobarpneumonia, bronchopneumonia DOAP: PH10.4. Describe parts of a correct, rational and legible prescription and write rational prescriptions for the provided condition. (examples of conditions to be used are				
Tuesday	LGT. PH5.2. Explain types, salientPK/PD, therapeutic uses, adverse drug reactions of drugs used for cough management.	LGT PA 25.3Etiopathogenesisandclassification of COPD, emphysema, chronic bronchitis and bronchiectasis		DOAP PA 25.7 DOAP: PH10.4. Describe parts of a correct, rational and legible prescription and write rational prescriptions for the				
Wednesday	SGT: MI 6.1, 6.2, 6.3			DOAP MI 7.4 Gram Stain/ Albert-stained sn	near of throat swab and of			

	Bacterial Meningitis	LGT. PH6.1. Explain types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of drugs used in Acid peptic diseases including Peptic Ulcers, GERD and		SGT PA 22.2 ,22.3 Describe abnormal findings in body fluids, Semen Analysis
Thursday	OG8.8 LGT Enumerate the investigations in pregnancy and describe	SGT PA 25.5 Define and describe the etiology, types, exposure, environmental influence, pathogenesis, stages, morphology, microscopic appearance and complicationsofOccupationallungdisease		DOAP MI 7.4 Gram Stain/ Albert-stained smear of throat swab and of SGT PA 22.2 ,22.3
Friday	SGD 9.1 Treatment of	SGT: MI 6.1, 6.2, 6.3 Viral Meningitis		AETCOM Module 2.8 What does it mean to be a family member Session 3 & 4:SDL: 2hr
Saturday	LGT GM26.25 Dengue	LGT. PH6.2. Describe types, salient pharmacokinetics, pharmacodynamics, therapeutic uses, adverse drug reactions of prokinetics & drugs used for emesis and antiemetics	SGT FM 9.3 Poisoning by Arsenic, lead, mercury, copper, iron, cadmium	

	Week 26: 30 th March 2026 to 4 th April 2026							
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM			
Monday	LGT:PA25.6,PA 26.7Tumors of lungandpleura including Mesothelioma	SGT: MI 6.1, 6.2, 6.3 Fungal and Parasitic Meningitis		DOAPPA25.7GrossandmicroscopicfeaturesofSCC lung, Small cell carcinoma lung				
				Discussion and File Checking				
Tuesday			HOLIDAY Mahavir Jayanti					

Wednesday	FORMATIVE ASSESSMENT MI 6.1- 6.3 Central Nervous System infections	LGT. PH6.3 Drugs used for diarrhoea and plan to manage acute and chronic diarrhea LGT. PH6.5. Describe s drugs used for		DOAP MI 7.5 Gram Stained & Acid-fast stained smear of DOAPPA25.7Grossandmicroscopicfeaturese cell carcinoma lungDescribe abnormal findir	_
Thursday	OG 14.1 LGT Enumerate and discuss diameters of maternal pelvis and	AITO: Tuberculosis: LGT PA25.4 GM 27.8Nesting Define and describe the etiology, types, pathogenesis, stages, morphology microscopic		AETCOM Module 2.8 What does it mean to be a family member Session 5: Discussion and closure 1hr	CPC Tuberculosis Pathology
Friday			Holiday GOOD FRIDAY		
Saturday	LGT GM26.20 Rickettsial diseases	LGT. PH6.4. drugs used for the management of constipation and devise management plan for a case of constipation	SGD FM -Feedback and FM 8.9, Poisoning with Ammonia, carbon monoxide, hydrogen		

		Week 27: 6 th A ₁	pril 2026 to 11 th April	2026	
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM
Monday	INTERNAL ASSESMENT -II (Theory) LGT: MI 7.1,7.2,7.3 Etio-pathogenesis, laboratory diagnosis and prevention of Infections of the upper respiratory tract caused by bacteria				MENT (PRACTICAL) itus. DOAP. PH 7.1, Devise plan for gement of Diabetes
Tuesday	AITO Diabetes mellitus. LGT. PH 7.1, GM 11.18 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in diabetes mellitus (Nesting)	AITO PA23.5 Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine and appendix GM 27.3 Nesting FORMATIVE ASSESMENT AND FEEDBACK PA 24	and INTERNAL ASSESMENT (PRACTICAL)		itus. DOAP. PH 7.1, Devise plan for gement of Diabetes se the Importance of patient preference while
Wednesday	LGT: MI 7.2, 7.3 etiopathogenesis, laboratory diagnosis and prevention of Infections of the lower respiratory tract caused by bacterial, mycobacterial, viral, fungal and parasitic agents	SGD. AITO Diabetes mellitus. PH 7.1 Devise management for an obese and non-obese diabetic patient & also comment on prevention of complications of the diabetes. (Nesting)		DOAP 19.5 AITO: Define and describe	DOAP MI 7.5 GM 27.10 GM27.2Nesting. d-fast stained smear of sputum/BAL/tracheal Tuberculosis: SGTPA25.4 GM 27.9 Sharing the etiology, types, pathogenesis, stages, opic appearance and complications of mph node AITO
Thursday	OG13.1 (a) & (b) LGT Discuss physiology of normal labour and different stages of normal labour.	AITO CAD/MI Session 1:LGT: 1hr-PA26.1,26.2,26.3, Arteriosclerosis, Atherosclerosis, Aneurysms and Heart failureAN5.8, GM2.4 PY5.1 Nesting FormativeAssessment & RefLGTtions((PA25)		AITO: Tuberculosis: DOAP MI 7.5 5 GM 27.10 GM27.2Nestin .Gram Stained & Acid-fast stained smear of sputum/BAL/trached DOAP 19.5 AITO: Tuberculosis: SGTPA25.4 GM 27.9 Sharing Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis, TB Lymph node AITO ASSESMENT	
Friday	LGT CM5.5 Describe the methods of nutritional surveillance	LGT: MI 7.1,7.2,7.3 Etio-pathogenesis, laboratory diagnosis		CPC (Shock)	AITO: TuberculosisMI: LGTNesting PA3.3 Chronic inflammation including

Saturday	LGT GM 26.9, 26.10, 26.28 Liver abscesses/ diarrheal diseases, Amebiasis	LGT. PH 7.1. Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in diabetes mellitus	FAMILY ADOPTION PROGRAMME VISIT 6	

		Week 28: 13 th April 2026 to 18 th April 2026							
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM –	02:00 PM -03:00 PM	03:00 PM -04:00 PM				
Monday	SUMMATIVE ASSESSMENT -II		SUMMATIVE ASSESSMENT -II		SUMMATIVE ASSESSMENT -II			AITO Hypertension, PA22.1BC 14.19 abnormal urinary findings s in a clinic	
				AITO TB. PH8.5 DOAP Explain the therapeutic uses and adverse effects of	* *				
Tuesday	dynamics, therapeutic uses, adverse drug Congenital Heart diseases,			AITO Hypertension, PA22.1BC 14.19, GM8.12. Correlation. Describe abnormal urinary findings s in a clinical specimen					
	reactions of drugs used in osteoporosis and devise management plan for a female and male patient with	RifetinaticHeart Disease		AITO TB. PH8.5 DOAP Explain the therapeutic uses and adverse effects of	* *				
Wednesday	CASE STUDIES PA 26	SGT. AITO Thyroid PH7.3, PY 8.3 Describe the types, kinetics, dynamics, adverse drug		PRACTICAL ASSESSMENT -II					
	reactions of drugs used in thyroid Disorders and devise a management plan for a case with thyroid Disorder (Nesting)			AITOCAD/MISGT:2hrs PA26.6 Ische Nesting Interpretabnormalitiesincardia	<i>'</i>				
Thursday	OG14.1SGD	SGT PA 26.7 Infectiveendocarditis		PRACTICAL ASSESSMENT -II					
	Describe and discuss physiology of lactation.			AITOCAD/MI:SGT:2hrs PA26.6 Isch ,AN5.8,GM2.4,2.9 Nesting Interpretabnormalitiesincardiacfunction					

Friday	LGT CM5.6 Enumerate and discuss the National Nutrition Policy,	LGT: MI 7.1,7.2,7.3 Etio-pathogenesis, laboratory diagnosis		LGT: MI 7.2, 7.3 Tuberculous and non-Tuberculous	LGT: MI 7.2, 7.3 Tuberculous and non-
Saturday	LGT GM26.17 Enteric fever and gram negative disease		LGT CM		

	Week 29: 20 th April 2026 to 25 th April 2026					
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM –	02:00 PM – 03:00 PM	03:00 PM –	
Monda y	LGT PA 26.9, Cardiomyopathies-types,pathogenesisand morphology. Etiopathogenesis, pathology and complications	SGT: MI 7.3 Etiological agents of lower respiratory infection in specific situations like age, immune status of community-acquired pneumonia.		AITO CAD/M ASSESMENT ,REFLGTTION FEEDBACK DOAP: PH10.3 Toprepareande	NS AND	
Tuesda y	SGT. AITO Thyroid. PH7.3, GM12.3 Describe the types, kinetics, dynamics, adverse drug reactions of drugs used in thyroid Disorders and devise a management plan for a case with thyroidDisorder (Nesting)	SGT PA,,26.10 Tumors of CVS		, AITO CAD/M ASSESMENT ,REFLGTTION EEEDDACK DOAP: PH10.3 Toprepareande	NS AND	
Wednes day	SGT: MI 7.3 Etiological agents of lower respiratory infection in specific situations like age, immune status of hospital-acquired pneumonia.	LGT. PH.7.4. Describethetypes,MOA,adverseeff ects,indications and contraindications of the drugs		DOAP MI 7.5 Gram Stained of DOAPPA26.1, Atheroma, MI,	26.6,26.8	

Thursda y	OG1.1 LGT Define & discuss birth rate, maternal mortality & morbidity. OC1.21 CT	LGTPA 27.1-27.2 Normalhistologyofkidney, Classify clinical Syndromes ,Renal failure- types,pathogenesis, clinical and laboratory findings		DOAP MI 7.5 Gram Stained of DOAPPA26.1, Atheroma ,MI,	26.6,26.8
Friday	SDL CM5.10 Recommend a dietary plan for a person with DM/ HTN/ Obesity in a simulated environment/FAP/Clinical posting	LGT: MI: 8.1:8.4 Etiopathogenesis and the laboratory		SGT: MI: 8.1:8.4	SDL: MI:
Saturda y	LGT GM 26.11 Urinary Tract Infections, Pyelonephritis, and Prostatitis	LGT. PH.7.5.Explain the types, PK/PD, adverse effects, indications and contraindications of corticosteroids and communicate to patient the	LGT: MI 8.2, 8.4 Common sexually transmitt ed		

	Week 30: 27 th April 2026 to 02 nd May 2026				
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM
Monday	LGTPA 27.3-27.4 AcuteandchronicRenalfailure-types,causes, pathogenesis FormativeAssessment&RefLGTtions((PA26)	FORMATIVE ASSESSMENT MI 7.1-7.4 Respiratory tract infections		PA 22.5 RENAL FUNCTION TO Certifiable Competency Assess PH10.3. Toprepareand explainal drugsforagiven case/condition	ment: DOAP:
Tuesday	LGT. PH7.6. PH.7.9. Describe the types, PK/PD, adverse effects, indications and contraindications of Androgens and drugs used of Erectile Dysfunction and Infertility	LGTPA 27.5 Defineandclassifyglomerulardiseases, Etiopathogenesis of glomerular injury, Glomerulonephritis		PA 22.5 RENAL FUNCTION TESTS DOAP Certifiable Competency Assessment: DOAP: PH10.3. ToprepareandexplainalistofP-	
Wednesday	SGT: MI 8.2, 8.4 Common sexually transmitted infections (STI), their pathogenesis, laboratory diagnosis and prevention of common viral sexually transmitted infections	LGT. PH7.7. Explain the types, PK/PD, adverse effects, indications and contraindications of drugs which modify Female Reproductive Functions including contraceptives. Explain the important instruction for use of female and male		OSPE MI 10.3 Demonstrate hand washing, practical observation DOAP 22.5 Interpret abnormal renal function tests (CERTIFIABLE COMPETENCY)	
Thursday	OG1.3 SGD Define & discuss still births and abortion with VI Integration with Forensic	LGTPA 27.6 Etiopathogenesis ,Pathology, clinical manifestations ,lab findingsandcomplications of IgA nephropathy		DOAP MI 7.5 Gram Stained & Acid-fast stained DOAP 22.5 Interpret abnormal (CERTIFIABLE COMPETENCE)	renal function tests
Friday			Holiday BUDH PURNIMA		
Saturday	LGT GM 26.12 Encephalitis and meningitis	LGT. PH7.8. Explain the types, kinetics, dynamics, adverse effects, indications and contraindications of uterine relaxants and stimulants.	SGD FM Summative Assessment		

	Week 31: 04 th May 2026to 09 th May 2026				
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM – 01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM
Monday	LGTPA 27.7 1hr Glomerularmanifestationsofsystemicdisease	LGT: MI 8.2, 8.4 Etio-pathogenesis and clinical courseof differentclinical and epidemiologicaltypes of urinary tract infections		SGTPA27.12,Genetics,inherita etiopathogenesisofcysticdisease DOAP: PH10.4. Describe parts legible prescription and write ra	of a correct, rational and
Tuesday	SDL: PH.9.4 Describe basics of vaccine use and types of vaccines	LGTPA 27.10, 27.13 AcuteandchronicpyelonephritisReflux nephropathy, Obstructive uropathy, renal stones		SGTPA27.12, Genetics, inheritance and etiopathogenesis of cystic disease of the kidney DOAP: PH10.4. Describe parts of a correct, rational and legible prescription and write rational prescriptions for	
Wednesday	SGT: MI 8.2, 8.4 Appropriate methodfor specimen colLGTtion and thelaboratory diagnosis of differentclinical and epidemiological types of urinary tract infections	LGT. PH8.1. Discuss general principles of chemotherapy with emphasis on antimicrobial resistance. PH8.2. Discuss rational use of antimicrobials and describe antibiotic stewardship program of your institute		OSPE MI 10.3 Demonstrate hand washing, pra SGTPA27.15 Etiology, genetics, pathogenesi featuresandprogressionofthrom	s, pathology, presenting
Thursday	OG8.6 LGT/SGD Describe and discuss nutrition in pregnancy & Lactation.	SGTPA27.8-27.9 Diseasesoftubularinterstitium,ATN		OSPE MI 10.3 Demonstrate hand washing, pra SGTPA27.15 Etiology, genetics, pathogenesi	
Friday	SGD FM Summative Assessment Feedback	LGT: MI 8.2, 8.4 Common sexually transmitted infections		SGT: MI 9.1, Zoonotic infections, etio-patho	genesis,
Saturday	LGT GM Assessment	LGT. PH8.3. Explain the PK/PD, adverse effects, indications of the following antibacterial drugs: Sulphonamides Quinolones, Beta- lactams, Macrolides, Tetracyclines, Aminoglycosides, and	FAMILY ADOPTION PROGRAMME VISIT 7		

	Week 32: 11 th May 2026to 16 th May 2026				
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM – 04:00 PM
Monday	LGTPA 27.11 Etiology, pathogenesis pathology, laboratory, urinary findings, distinguishing features progression and complicationsofvasculardiseaseofthe kidney	FORMATIVE ASSESSMENT MI 8.1-8.4 Genitourinary and Sexually Transmitted Infections		DOAPPA 27.7,27.10Diabeticnephropathy. hritis Tutorial: Endocrine	Chronicpyelonep
Tuesday	SDL: PH.9.4 Describe basics of vaccine use and types of vaccines	LGTPA27.14Classifyanddescrib ethe etiology, genetics, pathogenesis, pathology, presenting features, progression and spread of renal tumors		DOAPPA Diabeticnephropathy,Chronicpy Tutorial: Endocrine	27.7,27.10, velonephritis
Wednesda y	SGT: MI 9.1, Risk factors, laboratory diagnosis, and preventive & control strategies of different zoonotic infections caused by bacterial, viral, fungal and parasitic agents	LGT. PH8.3. Explain the PK/PD, adverse effects, indications of the following antibacterial drugs: antibacterial drugs PH8.4. Devise a pharmacotherapeutic plan for UTI and STDs		OSPE MI 10.3 Demonstrate hand washing, practical observation Tutorial –Glomerulonephritis	
Thursday	OG 9.3 LGT Discuss aetiology, clinical features, differential diagnosis	LGTPA 27.16 Describe the etiology, genetics, pathogenesis, pathology, presenting featuresandprogressionofurotheli		OSPE MI 10.3 Demonstrate hand washing, pract Tutorial –Glomerulonephritis	tical observation
Friday	SGD FM 9.6, 13.1 Describe toxic pollution of environment, its	SGT: MI 9.2 Describe the etiopathogenesis		SGT: MI 9.4 Oncogenic viruses in the develop	ment

Saturday	AITO Hypertension CM 5.10. Recommend a dietary	LGT. PH8.5. Explain the	SDL: MI	LGT:	
	plan for a person with DM/ HTN/ Obesity in a	types, kinetics, dynamics,	9.5	MI: 9.6	
	simulated environment, CM 5.15, GM8.5.CM 5.20		Describe	Describe	
	Counsel for diet modification for a diabetic/	therapeutic uses and	the	the	
	hypertensive/obese individual CM 5.21, G.13	adverse effects of drugs	concept	National	
	(Nesting)	used in tuberculosis.	of	Health	
			emerging	Programs	
		Devise management plan	& re-	in the	
		for tuberculosis treatment	emeroino	nreventio	

	Week 33: 18 th May 2026to 23 rd May 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGTPA 28.1,28.2 Testiculartumors,Carcinomapenis	SGT MI 9.2,9.3,9.4,9.5 Opportunistic infections		DOAPPA27.17 Grossandmic Adenocarcinoma kidney, Tran carcinoma	-	
				DOAP: PH1.13. Identify and describe the management of drug interactions		
Tuesday	LGT. PH8.6. Discuss the types, Kinetics, dynamics, adverse effects for drugs used for	SGTPA28.3,28.5 Pathogenesis,clinicalfeaturesand tests for benign prostatic hyperplasia		DOAPPA27.17Grossandmicr Adenocarcinoma kidney, Trai	-	
	Leprosy and outline management of Lepra reactions	Etiopathogenesisandprogressionof prostatitis FormativeAssessment&Feedback(PA27)		DOAP: PH1.13. Identify and management of drug interaction		
Wednesday	SGT MI 9.2,9.3,9.4,9.5 Post-transplantation infections	LGT. PH8.7. Discuss drugs used for 1.Amoebiasis 2. Kala-azar		OSPE MI 10.3 Demonstrate donning- doffing	g of PPE practical	
		3.Malaria 4. Filariasis		DOAPPA28.6Grossand microscopic features of Semin Adenofibromyomatoushyperp		
Thursday		LGTPA 28.4 Pathogenesis,diagnostictests,progression and		OSPE MI 10.3 Demonstrate donning- doffing	g of PPE practical	
		spread of carcinoma prostate		DOAPPA28.6Grossand microscopic features of Semin	noma testis,	
Friday	SDL CM5.10 Recommend a dietary plan for a person with DM/ HTN/	SGT: MI: 9.6 Describe the National Health Programs in the		SDI MI 9.2,9.3,9.4,9.5		
Saturday	LEC CM 5.9	LGT. PH8.7. Discuss drugs used for 1.Amoebiasis 2. Kala-azar 3.Malaria 4. Filariasis	FAMILY ADOPTION PROGRAMME VISIT 8			

	PROPOSED VACATION Week 34: 25th May 2026to 31 stMay 2026								
		Week 35: 1 st June 2026to 6 th June 2026							
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM				
Monday	LGT PA 29.1 Epidemiology, pathogenesis, screening, diagnosis andprogressionofCarcinomacervix	SGT MI 9.2,9.3,9.4,9.5 Laboratory acquired infections		SGTPA29.6 Etiologyandmorphologicalfeat	uresof cervicitis				
	andprogressionorearchiomacervix			DOAP: PH1.13. Identify and d drug interactions	lescribe the management of				
Tuesday	SDL. PH. 9.5. Describe types, precautions and uses of Antiseptics	LGTPA29.2,29.3. Etiopathogenesis , Morphology, clinical features		SGTPA29.6 Etiologyandmorphologicalfeat	uresof cervicitis				
	and Disinfectants	Leiomyoma .leiomyosarcoma, carcinoma endometrium			lescribe the management of				
Wednesday		LGT. PH8.8. Explain the types, kinetics, dynamics, adverse effects of drugs used for fungal infections							
Thursday		SGT PA29.7-29.9Endometriosis, adenomyosis, endometrial		REVISION/ LOG BOOK CHECKING					
		hyperplasia		REVISION/ LOG BOOK CE	HECKING				
Friday	LGT CM5.11 Plan a diet for an adult which meets the protein (macro	SGT MI 9.2,9.3,9.4,9.5 Transfusion transmitted infections		LGT: MI 10.2 Standard&transmission-based	precautions for				
Saturday	Internal assessment	LGT. PH8.9. Discuss the types, kinetics, dynamics, adverse effects of drugs used for Intestinal Helminthiasis	SUMMATIVE ASSESSMENT						

	Week 36: 8 th June 2026 to 13 th June 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM –	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	LGTPA29.4-29.5Ovarian tumors ,Gestational trophoblasticneoplasms	SGT MI 9.2,9.3,9.4,9.5 Zoonotic infections		DOAPPA 29.10 GrossandmicroscopicfeaturesofCacervix,Benigr cystic teratoma, Leiomyoma, Ca endometrium			
				Certifiable Competency Assessment. PH1.13. Identify and describe the management of drug interactions			
Tuesday	SDL. PH. 9.5. Describe types, precautions and uses of Antiseptics and Disinfectants	SGTPA30.1,30.4 Classifyanddescribethetypes, etiology, pathogenesis ofbenign breast disease, etiopathogenesisof gynecomastia		DOAPPA29.10 Grossandmicroscopicfe	aturesofCacervix,Benign		
	breast disease, etiopatnogenesisor gynecomastia			Certifiable Competend Identify and describe th	ey Assessment. PH1.13. e management of drug		
Wednesday	SGT MI 9.2,9.3,9.4,9.5 Congenital infections	LGT. PH8.10. Discuss the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs used for viral		OSPE MI 10.3 Demonstrate segregatio	n of Biomedical waste		
		diseases including HIV		DOAPPA305Grossand Fibroadenoma, Infiltrati	•		
Thursday	CMS20. Describe and discuss the paidemiological and control measures including the pridemiological and control measures including the pridemiology and control measures are pridemiological and control measures and control measures are pridemiological and control measures and control measures are pridemiological and co			OSPE MI 10.3 Demonstrate segregatio	n of Biomedical waste		
	epidemiological and control measures including the use of essential laboratory tests at the primary care level for diabetes (Sharing).	the breast, Phyllodes tumor FormativeAssessment&Feedback(PA29)		DOAPPA30.5Grossand Fibroadenoma, Infiltrati	_		

Friday	LGT CM5.12 Demonstrate different types of breastfeeding holds, latching, manual expression	LGT: MI: 10.1 Types of Healthcare- Associated Infections (HAI). Define		
Saturday		LGT. PH8.10. Discuss the types, kinetics, dynamics, adverse effects, indications and contraindications of drugs used for viral diseases including HIV		

	Week 37: 15 th June 2026 to 20 th June 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	LGT PA 34.2 Etiology, pathogenesis, presentationandcomplicationsofCNS tumors	FORMATIVE ASSESSMENT MI 9.1- 9.6 Zoonotic diseases and Miscellaneous		SGTPA34.1,34.3 Etiology,pathogenesisanddifferentiatingfeaturesofmeningitis, Etiology of meningitis based on given CSF parameters DOAP: PH10.4. Describe parts of a correct, rational and legible			
	GVN A LATIN TO A GONG CONTINUE A			prescription and write rational presc	riptions for the provided condition.		
Tuesday	SUMMATIVE ASSESSMENT 2			SGTPA34.1,34.3 Etiology pathogenesisanddifferentia	tingfeaturesofmeningitis. Etiology		
				DOAP: PH10.4. Describe parts of a correct, rational and legible prescription and write rational prescriptions for the provided condi			
Wednesday	SDL: MI 10.4: Hospital surveillance and significance of	LGT. PH8.11. Describe the types, kinetics, dynamics,		OSPE MI 10.3 Demonstrate donning- doffing of PPE practical observation with			
	assessing the microbial contamination of food, water and air (in hospital surveillance	adverse effects, indications and contraindications of anti-cancer drugs. Devise plan for amelioration of		DOAPPA34.3CertifiableIdentifytheetiologyofmeningitis based on CSF parameters DOAPPA35.3CertifiableIdentifytheetiologyofmeningitis based on CSF parameters			
Thursday		LGT PA 35.1		OSPE MI 10.3 Demonstrate donning- doffing of PF	E practical		

	AITO Tuberculosis CM8.3 GM 27.17 Sharing. Enumerate and describe disease specific	Etiopathogenesis, Genetics, Morphology of		DOAPPA34.3CertifiableIdentifytheetiologyofmeningitis based on given CSF parameters
Friday	LGT CM5.13 Counsel a mother about complementary feeding for different age groups	SGT: MI 10.2, 10.5 Commonly detected drug-		
Saturday		LGT. PH8.11. Anticancer drugs	LGT CM5.14, CM5.15, CM5.16	

	Week 38: 22 nd June 2026 to 27 th June 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM –	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	INTERNAL ASSESMENT -III(Theory) SGT MI 9.2,9.3,9.4,9.5 Oncogenic micro-organisms			INTERNAL ASSESMENT -I	II (PRACTICAL)		
				DOAP: PH10.4. Describe parts			
Tuesday	SDL. PH9.2. Describe management of common drug poisonings, insecticides, common stings and bites	AITO THYROIDLGT 1 Hr.PA 31.1 PY8.3 AN35.8 Enumerate, classify and describe		INTERNAL ASSESMENT -III (PRACTICAL)			
	the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings SHARING			DOAP: PH10.4. Describe parts of a correct, rational and legible prescription and write rational prescriptions for the			
Wednesday	SGT: MI 10.5 The mechanism of evolution, spread, and control of antimicrobial drug resistance in hospitalized patients	LGT. PH9.3. Describe chelating agents and make a plan for management of heavy metal poisoning		DOAP: Revision Perform Gram stain, ZN stain, a			
				PA 31.2 AITO SGT 1 hr Descr	ibe the etiology, cause,		
Thursday				DOAP: Revision Perform Gram stain, ZN stain, a	and routine stool		

	AITO Hypertension. SGT. CM8.2 Describe and discuss the epidemiological and control measures including Hypertension. CM 8.3 Enumerate and describe disease specific National Health Programs	AITO LGT 1 Hour PA31.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of hypothyroidism	PA 31.2 AITO SGT 1 hr Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis LINKER CASE GM 12.1CORRELATION
Friday	LGT CM5.17, CM5.22 Ability to counsel mothers on breast feeding with focus on attachment to breast and correct position of the newborn	MI 11.1, 11.2, 11.3 Antimicrobial spectrum of important human pathogens and its application in clinical therapy.	
Saturday		LGT. PH9.6 Describe drugs used in various skin disorders like acne vulgaris, scabies	

	Week 39: 29 th June 2026 to 4 th July 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	AITO LGT 1 hrPA31.4 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features & complications of Thyroid tumors	MI 11.1, 11.2, 11.3 Explain intrinsic & acquired drug resistance		DOAPPA31.1- 31.3Grossandmicroscopi Summative Practical Ass			
Tuesday	SDL. PH9.2. Describe management of common drug poisonings, insecticides, common stings and bites	AITO LGT 1Hr. PA22.3 BI 14.19 Describe and interpret the abnormalities in a panel thyroid function tests NESTING		DOAPPA31.1- 31.3Grossandmicroscopi Summative Practical Ass			

Wednesday	MI 11.1, 11.2, 11.3 The genotypic & phenotypic mechanisms of antimicrobial drug Resistance	PH9.7. Describe drugs used in glaucoma and other ocular disorders including topical (ocular) drug delivery systems		OSPE MI 10.3 Demonstrate segregation of Biomedical waste practical observation with checklist CPC-Amyloidosis, Tuberculosis
Thursday		LGTPA 31.6 Etiology,genetics,pathogenesis, manifestations, laboratory and morphologic features of hyperparathyroidism FormativeAssessment &Feedback(PA29, 30)		OSPE MI 10.3 Demonstrate segregation of Biomedical CPC-Amyloidosis, Tuberculosis
Friday	LGT CM5.18 Ability to counsel mothers on complementary feeding	MI 11.1, 11.2, 11.3 Methods of antimicrobial susceptibility testing,		
Saturday		LGT. PH9.1. Describe the types, kinetics, dynamics, therapeutic uses, adverse drug reactions of	LGT CM5.19, CM5.20, CM5.21	

	Week 40: 6 th July 2026 to 11 th July 2026						
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM		
Monday	SGTPA31.8,31.9 Describe the etiology, pathogenesis adrenal	MI 11.1, 11.2, 11.3 The concept and application of the antimicrobial stewardship program		DOAP 31.10 Adrenal neoplasms			
	insufficiency. Cushing's syndrome	The state of the s		Certifiable Competency Asso parts of a correct, rational and			

Tuesday	Revision G. Pharmacology	AITO LGT 1 Hr PA 31.5,GM11.1,11.3 PY8.6 Classify and describe the epidemiology, etiology, of diabetes mellitus LINKER CASE NESTING		DOAP 31.10 Adrenal neoplasms Certifiable Competency Assessment: PH10.4. Describe parts of a correct, rational and legible prescription and write
Wednesday	FORMATIVE ASSESSMENT MI: 10.1-10.5 Healthcare-associated infections (HAI)	Revision G. Pharmacology	TUTORIAL- ENDORINE SYSTEM	Revision / log Book / Practical file checking Revision / log Book / Practical file checking
Thursday		AITO SDL 1 hr PA 31.5 DIABETES MELLITUS		Revision / log Book / Practical file checking Revision/ log book / Practical file checking
Friday	LGT CM10.1 Describe the current status of Reproductive, maternal, newborn and Child Health	SGT: MI Sterilization and Disinfection		MI 11.1, 11.2, 11.3 Rational antimicrobial prescription and your role in its implementation
Saturday		Revision ANS	SUMMATIVE ASSESSMENT	

Week 41: 13 th July 2026 to 18 th July 2026

Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM
Monday	LGTPA31.7 Pancreatic cancer	FORMATIVE ASSESSMENT MI 11.1-11.3	Clinical Postings END	DOAPinstruments Revisionof Grossspecimens	
	Antimicrobial resistance (AMR) & Antimicrobial Stewardship (AMS)			Revision: CAL	
Tuesday	Revision: ANS	Case studies -Kidney		DOAPinstruments Revisionof Grossspecimens Revision: CAL	
Wednesday	SGT: MI 10. 2, 10.3,10.4 Occupational hazards	Revision. CNS 1	CASE STUDIES- CVS,	OSPE MI 10.3 Demonstrate segregation of Biomedical TUTORIAL -Hepatobiliary	
Thursday		AITO SDL 1 hr PA 31.5 DIABETES MELLITUS		OSPE MI 10.3 Demonstrate segregation of Biomedical	
				TUTORIAL-Hepatobili	iary
Friday	SDL CM10.3 Describe local customs and practices during pregnancy, child birth, lactation and child feeding practices	LGT: MI 10. 2, 10.3,10.4 Bioterrorism- Microbes in biological warfare.	TUTORIAL- GIT	DOAP: Revision Perform Gram stain, ZN stain, and routine stool examination to identify the different	
Saturday		Revision. CNS 2	LGT CM10.2, CM10.4, CM10.5		

		Week 42: 20 th July 2026	to 25 th July 2026			
Day	08:00-09:00 AM	09:00 -10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM	03:00 PM -04:00 PM	
Monday	LGTPA 32.3 Classifyanddescribetheetiology, pathogenesis, manifestations, radiologic features of soft tissue tumors			REVISION OF CERTIFIABLE COMPETENCY		
				Revision: Routes of administration	on using Manikins	
Tuesday	Revision CVS	SDL PA 32.2 Classifyanddescribe the etiology, pathogenesis, manifestations,		REVISION OF CERTIFIABLE COMPETENCY Revision: Routes of administration using Manikins		
		radiologic and morphologic features of bone tumors				
Wednesday		Revision CVS	TUTORIAL- MALE GENITAL SYSTEM	OSPE MI 10.3 Demonstrate segregation of Biomedical waste practical observation with checklist		
				DOAP PA 32.2Gross and micros Bone	scopic features of	
Thursday		SGT PA 32.1, 32.4 Classify and describetheetiology,pathogenesis, manifestations, radiologic and		OSPE MI 10.3 Demonstrate segregation of Biomedical waste p		
		morphology features and complications of osteomyelitis		DOAP PA 32.2Gross and microscopic features of Bone		
Friday	LGT CM10.6 Enumerate and describe various family planning methods, their advantages and		CPC- HEPATOBILLARY	DOAP: Revision Perform Gram stain, ZN stain, ar	nd routine stool	

Saturday		Revision CVS	LGT CM10.7, CM10.8, CM10.9,			
	Week 43: 27th July 2026 to 1st August 2026					
Day	08:00-09:00 AM	09:00 –10:00 AM	10:00 AM -01:00 PM	02:00 PM -03:00 PM		
Monday	SGTPA32.5 Etiology,immunology,pathogenesis, manifestations,complicationsofrheumatoidarthritis,	SUMMATIVE ASSESSMENT - III		CASE STUDY (MI/ DIABETES) Revision: Routes of administration using Manikins		
	osteoarthritis, gouty arthritis					
Tuesday	Revision CVS	SDL PA32.2 Classifyanddescribe the etiology, pathogenesis,		CASE STUDY (MI/ DIABETES) Revision: Routes of administration using Manikins		
		manifestations, radiologic and morphologic features of bone tumors				
Wednesday			CASE STUDIES- LIVER,KIDNEY	PRACTICAL ASSESSMENT - III		
				REVISION OF SLIDES AND FI	INAL LOG BOOK	
Thursday		CPC (KIDNEY)		PRACTICAL ASSESSMENT - III		
				REVISION OF SLIDES AND FINAL LOG BOOK CHECKING		
Friday	SDL CM10.3 Describe local customs and practices during pregnancy, child birth, lactation	PHARMACOLOGY	CASE STUDIES- HAEMATOLOGY	DOAP: Revision Demonstrate hand washing, donning- doffing of PPE		
Saturday		Revision CVS	SUMMATIVE ASSESSMENT			

August and September- Sendups followed by University Final Exams	